23andme’s - QuikReader

23andMe reports sales decline a day after announcing plans to cut 40% of workforce

Embattled genetic testing provider 23andMe said Tuesday that revenue declined from a year earlier, a day after the company announced a cost-cutting plan.

Business - CNBC - 3 hours ago

23andMe’s stock falls after company says there’s substantial doubt it can stay in business

Shares of 23andMe fell 4% Tuesday after the DNA-testing company reported its latest quarterly loss and included “going concern” language in its financial statements, shedding gains made late Monday ...

Business - MarketWatch - 7 hours ago

23andMe cuts 40% of its workforce and discontinues therapeutics division

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs

Health - ABC News - 7 hours ago

Genetic testing firm 23andMe cuts 40% of its workforce amid financial struggles

Company says it will cut about 200 employees as value plummets in aftermath of huge data breach. The genetic testing firm 23andMe said on Monday it would cut about 40%, or 200 employees, from its ...

World - The Guardian - 8 hours ago

23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs

As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.

Business - Inc. - 9 hours ago

23andMe warns of ‘substantial doubt’ over its survival without new funding

Once-hyped genetic start-up issues latest guidance after reporting further quarterly revenue declines

Business - Financial Times - 9 hours ago

23andMe Lays Off 40% of Staff, Shuts Drug Development Business

The genetics company is closing a unit that was once seen as core to its future.

Business - The Wall Street Journal - 21 hours ago

DNA-testing site 23andMe to lay off 40% of its workers

The once-popular general DNA-testing firm holds a trove of sensitive genetic data from its customers.

23andMe to slash 40% of its workforce, end therapeutics program to cut costs

DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.

Business - MarketWatch - Yesterday

DNA-testing site 23andMe fights for survival

Once millions used it to find out about their family histories - this week it was almost delisted. What went wrong?

23andMe appoints three new board members following abrupt resignations

23andMe appointed three new independent directors to its board, the company said Tuesday.

Business - CNBC - October 29

Inside the fall of 23andMe

Once worth $6 billion, 23andMe has lost 98% of its value and is on the verge of being delisted from the Nasdaq. So what happened?

Business - CNBC - October 23

23andMe succumbs to a dismal genetic destiny

Was it nature or nurture? In the unhappy case of a DNA testing company and its sliding share price, the answer is both

Business - Financial Times - October 16

Founder Anne Wojcicki races to rescue 23andMe

Once-hyped genetic testing company hit by data breach, plunging share price and board resignations

Business - Financial Times - October 15

Here's how to delete your 23andMe data, as company flounders

Here's how to delete your data as company shake-up leaves customers wondering what will happen to their DNA info.

Latest in 23andme’s